Sort by:
Filters:
In the last seven days, 198 new articles where published in 25 top journals in the field of oncology.
Major topics on this page:
Nature reviews. Cancer | Journal Article | 2025 Apr
Dart A
No abstract available
Nature reviews. Cancer | Journal Article | 2025 Apr
Weichenthal S
No abstract available
The Lancet. Oncology | Journal Article | 2025 Apr
Lawler M and Others
No abstract available
Nature reviews. Cancer | Journal Article | 2025 Apr
Brewer G
No abstract available
The Lancet. Oncology | Journal Article | 2025 Apr
Hodge JC and Others
No abstract available
Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Letter | 2025 Mar 28
Wang X and Others
No abstract available
Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Journal Article | 2025 Apr
Blackstone EC and Others
No abstract available
The Lancet. Oncology | Published Erratum | 2025 Apr
No authors listed
No abstract available
The Lancet. Oncology | Letter | 2025 Apr
Vigarios E and Others
No abstract available
Cancer discovery | Journal Article | 2025 Apr 2
Cai L and Others
Intraoperative 13C-glucose infusions in patients with NSCLC show that tumors with high labeling of TCA cycle intermediates progress rapidly, resulting in metastasis and early death. Blocking this pathway suppresses metastasis of human NSCLC cells in mice.
Nature reviews. Cancer | Journal Article | 2025 Apr
Senft D
No abstract available
Cancer discovery | Journal Article | 2025 Apr 2
Su YJ and Others
Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.
The Lancet. Oncology | Journal Article | 2025 Apr
De Meerleer G and Others
No abstract available
Nature reviews. Clinical oncology | Journal Article | 2025 Apr
Tibau A and Others
No abstract available
Nature reviews. Clinical oncology | Journal Article | 2025 Apr
Ge C and Others
No abstract available
Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Journal Article | 2025 Mar 28
Bardia A and Others
No abstract available
Annals of oncology : official journal of the European Society for Medical Oncology | Letter | 2025 Apr
Zeng YC and Others
No abstract available
Nature reviews. Cancer | Journal Article | 2025 Apr
Coorens THH
No abstract available
Nature reviews. Cancer | Review | 2025 Apr
Moon CY and Others
Dendritic cells (DCs) are specialized antigen-presenting cells that are present at low abundance in the circulation and tissues; they serve as crucial immune sentinels by continually sampling their environment, migrating to secondary lymphoid organs and shaping adaptive immune responses through antigen presentation. Owing to their ability to orchestrate tolerogenic or immunogenic responses to a specific antigen, DCs have a pivotal role in antitumour immunity and the response to immune checkpoint blockade and other immunotherapeutic approaches. The multifaceted functions of DCs are acquired through a complex, multistage process called maturation. Although the role of inflammatory triggers in driving DC maturation was established decades ago, less is known about DC maturation in non-inflammatory contexts, such as during homeostasis and in cancer. The advent of single-cell technologies has enabled an unbiased, high-dimensional characterization of various DC states, including mature DCs. This approach has clarified the molecular programmes associated with DC maturation and also revealed how cancers exploit these pathways to subvert immune surveillance. In this Review, we discuss the mechanisms by which cancer disrupts DC maturation and highlight emerging therapeutic opportunities to modulate DC states. These insights could inform the development of DC-centric immunotherapies, expanding the arsenal of strategies to enhance antitumour immunity.
Blood cancer journal | Letter | 2025 Apr 3
Hoff FW and Others
No abstract available